Drug Prices and Third Party Payment
- 1 April 1994
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 5 (4) , 343-350
- https://doi.org/10.2165/00019053-199405040-00008
Abstract
The growing burden of prescription drug costs has focused attention on factors which influence physicians’ prescribing decisions. We hypothesised that third party coverage of prescription costs would elicit selection of expensive drugs, but that this tendency could be moderated by price reminders. In a mailed survey, primary care physicians throughout Ontario (n = 1072) were provided with the clinical scenario of a patient with an infectious exacerbation of chronic obstructive pulmonary disease, and asked to select diagnostic tests as well as 1 of 6 antibiotics. Two antibiotics were expensive (ciprolloxacin and cefaclor; average price $Can52.23). and 4 inexpensive [amoxicillin. couimoxazole (trimethoprim/sulfamethoxazole), erythromycin and tetracycline; average price $Can2.80]. Neither expensive drug is considered first line therapy for the condition described. Questionnaires differed in the presence or absence of drug benefit coverage and price information. The response rate was 71 %. With third party cost coverage and prices shown, 18% of respondents selected an expensive antibiotic. This increased to 38% when the prices were omitted [odds ratio 2.72; 95% confidence interval (CI) 1.61, 4.60; p < 0.001], and decreased to 8% when the patient was said to have no drug benefits coverage (odds ratio 0.40; 95% CI 0.19, 0.84; p < 0.01). On a control questionnaire in which neither cost coverage nor prices were specified. and in which respondents were asked to indicate the most appropriate antibiotic, 37% selected an expensive drug (relative to the version giving both prices and cost coverage: odds ratio 2.70; 95% CI 1.62, 4.53; P < 0.001). We conclude that inappropriate selection of expensive antibiotics is increased when the patient has full drug benefit coverage but reduced when physicians are reminded of drug prices. These results support assessment of a price-oriented educational intervention in an effort to reduce inappropriately expensive prescribing.Keywords
This publication has 20 references indexed in Scilit:
- Choosing between apples and applesJournal of General Internal Medicine, 1992
- The influence of an academic representative on prescribing by general practitioners.British Journal of Clinical Pharmacology, 1992
- The Effect of Drug Co-Payments on Utilization and Cost of Pharmaceuticals in a Health Maintenance OrganizationMedical Care, 1990
- Cost Effectiveness of Two Interventions for Reducing Outpatient Prescribing CostsDICP, 1989
- The use of antibiotics in acute bronchitis and acute exacerbations of chronic bronchitis.1988
- Payment Restrictions for Prescription Drugs under MedicaidNew England Journal of Medicine, 1987
- Antibiotics for Exacerbations of Chronic Bronchitis?The Lancet, 1987
- Economic and Policy Analysis of University-based Drug ???Detailing???Medical Care, 1986
- Improving Drug-Therapy Decisions through Educational OutreachNew England Journal of Medicine, 1983
- Scientific versus commercial sources of influence on the prescribing behavior of physiciansThe American Journal of Medicine, 1982